Maria Elena Dela Rosa, MSN, FNP-c, RN, is a board-certified family nurse practitioner with 22+ years of nursing experience taking care of oncology patients at the City of Hope National Medical Center. She graduated from the University of the Philippines Manila in 1993 with a Bachelor of Science degree in Nursing. She earned her Master’s in Nursing and Family Nurse Practitioner degrees at Azusa Pacific University in California USA in 2016. She joined the Hematology and Hematopoetic Cell Transplant Department at City of Hope in 2017 as a nurse practitioner taking care of patients with different hematologic malignancies such as AML, myelofibrosis, MDS, and Lymphoma. In the past 2 years, she has been specializing in the care of patients with different types of lymphomas. She provides physical assessments, symptom management, triage, education, counseling and coordination of care of these patients with complex needs. She is a participating clinician in different clinical trials for Chronic Lymphocytic Leukemia and Mantle Cell lymphomas. EDUCATION Master of Science in Nursing, Family Nurse Practitioner Graduation: December 17, 2016 Azusa Pacific University, Azusa, CA Bachelor of Science in Nursing University of the Philippines, Manila, Philippines, 1989-1993 LICENSES/CERTIFICATIONS Family Nurse Practitioner California Board of Nursing Board Certified Nurse Practitioner American Association of Nurse Practitioners (AANP) Registered Nurse California Board of Nursing AWARDS/ACTIVITIES/PROFESSIONAL ORGANIZATION : ● Daisy Award Winner September 2008, City of Hope National Medical Center ● Supporter, Relay for Life, Fundraiser 2013 • Presenter, Oncology Nursing Society Congress, Abstract poster of The phase 2 CAPTIVATE study: primary analysis of a fixed-duration cohort following first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma, April 2022, Anaheim, California • Nurse author, The phase 2 CAPTIVATE study: primary analysis of a fixed-duration cohort following first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma, published, online issue of Oncology Nursing Forum 2022 • Speaker, Abbvie Oncology Speaker Bureau • Speaker, Astrazeneca Speaker Bureau